OrthoEvra labeling change
Executive Summary
Updated labeling for OrthoMcNeil's contraceptive patch OrthoEvra will include results of a new epidemiology study that shows a higher risk of developing serious blood clots with the patch than with birth control pills., firm announces Jan. 18. The results support earlier studies and a warning that was added to labeling in 2005, noting that the transdermal formulation had higher exposure to contraceptive hormones than oral products. In 2006, the warning was revised with two epidemiology studies - one showing a higher risk of venous thromboembolism with the patch and one showing no difference based on the route of administration...
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.